| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Alessia Furgiuele, Marco Cosentino, Marco Ferrari, Franca Marin. Immunomodulatory Potential of Cannabidiol in Multiple Sclerosis: a Systematic Review. Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology. vol 16. issue 2. 2021-06-18. PMID:33492630. |
cannabinoids are endowed with remarkable immunomodulating properties, and in particular the non-psychotropic cannabinoid cannabidiol (cbd) is increasingly recognized as anti-inflammatory and immunosuppressive, nevertheless with excellent tolerability even at high doses. |
2021-06-18 |
2023-08-13 |
human |
| Jade Simões de Castro, Caio Henrique Pinke Rodrigues, Aline Thaís Brun. Journal of chemical information and modeling. vol 60. issue 4. 2021-06-17. PMID:32118417. |
for example, synthetic cannabinoids are sprayed on herbal products to reproduce the cannabis recreational effects. |
2021-06-17 |
2023-08-13 |
Not clear |
| Heidi Öblom, Claus Cornett, Johan Bøtker, Sven Frokjaer, Harald Hansen, Thomas Rades, Jukka Rantanen, Natalja Genin. Data-enriched edible pharmaceuticals (DEEP) of medical cannabis by inkjet printing. International journal of pharmaceutics. vol 589. 2021-06-17. PMID:32919002. |
quick response (qr) code patterns containing lipophilic cannabinoids, i.e., cannabidiol (cbd) and delta-9-tetrahydrocannabinol (thc), were printed using a desktop inkjet printer. |
2021-06-17 |
2023-08-13 |
Not clear |
| David Fabregat-Safont, Juan V Sancho, Félix Hernández, María Ibáñe. The key role of mass spectrometry in comprehensive research on new psychoactive substances. Journal of mass spectrometry : JMS. vol 56. issue 7. 2021-06-17. PMID:33155376. |
new psychoactive substances (nps) are a wide group of compounds that try to mimic the effects produced by the 'classical' illicit drugs, including cannabis (synthetic cannabinoids), cocaine and amphetamines (synthetic cathinones) or heroin (synthetic opioids), and which health effects are still unknown for most of them. |
2021-06-17 |
2023-08-13 |
Not clear |
| Rosa Maria Vitale, Fabio Arturo Iannotti, Pietro Amode. The (Poly)Pharmacology of Cannabidiol in Neurological and Neuropsychiatric Disorders: Molecular Mechanisms and Targets. International journal of molecular sciences. vol 22. issue 9. 2021-06-17. PMID:34062987. |
cannabidiol (cbd), the major nonpsychoactive cannabis constituent, has been proposed for the treatment of a wide panel of neurological and neuropsychiatric disorders, including anxiety, schizophrenia, epilepsy and drug addiction due to the ability of its versatile scaffold to interact with diverse molecular targets that are not restricted to the endocannabinoid system. |
2021-06-17 |
2023-08-13 |
Not clear |
| Gabor Xantus, Laszlo Zavori, Candice Matheson, V Anna Gyarmathy, Laszlo M Fazekas, Peter Kanizsa. Cannabidiol in low back pain: scientific rationale for clinical trials in low back pain. Expert review of clinical pharmacology. vol 14. issue 6. 2021-06-16. PMID:33861675. |
pattern analysis of cannabis users suggested that attempts to alleviate musculo-skeletal pain is often seen as a major drive to use cannabinoids. |
2021-06-16 |
2023-08-13 |
Not clear |
| Yanpei Wang, Chenyi Zuo, Wenchao Wang, Qinfang Xu, Lei Ha. Reduction in hippocampal volumes subsequent to heavy cannabis use: a 3-year longitudinal study. Psychiatry research. vol 295. 2021-06-15. PMID:33261923. |
cannabis exposure is related to neuroanatomical changes in brain regions rich in cannabinoid receptors, such as the hippocampus. |
2021-06-15 |
2023-08-13 |
Not clear |
| Alice Palermiti, Alessia Cafaro, Sebastiano Barco, Paolo Bucchioni, Paolo Franceschini, Jessica Cusato, Amedeo De Nicolò, Alessandra Manca, Elisa Delia De Vivo, Eleonora Russo, Francesco Cecchi, Federica Pigliasco, Flavia Lillo, Gino Tripodi, Antonio D'Avolio, Giuliana Cangem. Analysis of Cannabinoids Concentration in Cannabis Oil Galenic Preparations: Harmonization between Three Laboratories in Northern Italy. Pharmaceuticals (Basel, Switzerland). vol 14. issue 5. 2021-06-15. PMID:34069020. |
analysis of cannabinoids concentration in cannabis oil galenic preparations: harmonization between three laboratories in northern italy. |
2021-06-15 |
2023-08-13 |
Not clear |
| José Pedro Prieto, Ximena López Hill, Jessika Urbanavicius, Verónica Sanchez, Xavier Nadal, Cecilia Scorz. Cannabidiol Prevents the Expression of the Locomotor Sensitization and the Metabolic Changes in the Nucleus Accumbens and Prefrontal Cortex Elicited by the Combined Administration of Cocaine and Caffeine in Rats. Neurotoxicity research. vol 38. issue 2. 2021-06-14. PMID:32415526. |
in the last years, clinical and preclinical researchers have increased their interest in non-psychotomimetic cannabinoids, like cannabidiol (cbd), as a strategy for treating psychostimulant use disorders. |
2021-06-14 |
2023-08-13 |
rat |
| James V Gruber, Robert Holt. Purified Cannabidiol isolate does not inhibit active caspase-1 release in NLRP inflammasome-mediated UVB or ATP-activated keratinocytes or appear to reduce key inflammatory cytokines in UVB-irradiate keratinocytes. International journal of cosmetic science. vol 43. issue 3. 2021-06-14. PMID:33559194. |
cannabidiol is a plant-derived cannabinoid that has been suggested to have several human health benefits including potential anti-inflammatory effects. |
2021-06-14 |
2023-08-13 |
human |
| Deena Damsky Dell, Daniel P Stei. Exploring the Use of Medical Marijuana for Supportive Care of Oncology Patients. Journal of the advanced practitioner in oncology. vol 12. issue 2. 2021-06-12. PMID:34109050. |
the national academy of sciences (2017) reports conclusive or substantial evidence that cannabis is successful in treating chronic cancer pain and chemotherapy-induced nausea and vomiting, moderate evidence that cannabinoids are beneficial for sleep disorders that accompany chronic illnesses, and limited evidence supporting use for appetite stimulation and anxiety. |
2021-06-12 |
2023-08-13 |
Not clear |
| Maria Birgitte Søndermølle, Else Rander. [Cannabinoid hyperemesis syndromecan be relieved by hot showers]. Ugeskrift for laeger. vol 183. issue 15. 2021-06-11. PMID:33913422. |
this is a case report of a 19-year-old woman with cannabinoid hyperemesis syndrome (chs), which is characterised by cyclic vomiting and nausea, relieved by hot showers and caused by chronic cannabis usage. |
2021-06-11 |
2023-08-13 |
Not clear |
| Gorm Mørk Hanse. [Asymptomatic pneumopericardium in a young male cannabis smoker]. Ugeskrift for laeger. vol 182. issue 12. 2021-06-09. PMID:32285772. |
this is a case report of a 27-year-old man, who had a daily consumption of cannabis and presented with abdominal pain and nausea consistent with cannabinoid hyperemesis syndrome. |
2021-06-09 |
2023-08-13 |
Not clear |
| Andrew J Roebuck, Quentin Greba, Anna-Maria Smolyakova, Mariam Alaverdashvili, Wendie N Marks, Sumanta Garai, Samantha L Baglot, Gavin Petrie, Stuart M Cain, Terrance P Snutch, Ganesh A Thakur, Matthew N Hill, John G Howland, Robert B Laprairi. Positive allosteric modulation of type 1 cannabinoid receptors reduces spike-and-wave discharges in Genetic Absence Epilepsy Rats from Strasbourg. Neuropharmacology. vol 190. 2021-06-09. PMID:33845076. |
certain cannabinoids, such as cannabidiol (cbd), have shown promise in the treatment of pediatric epilepsies. |
2021-06-09 |
2023-08-13 |
rat |
| Keith A Kwan Cheung, Murray D Mitchell, Helen S Heussle. Cannabidiol and Neurodevelopmental Disorders in Children. Frontiers in psychiatry. vol 12. 2021-06-08. PMID:34093265. |
the cannabinoid cannabidiol, in particular, has been reported to be safe and well-tolerated with a plethora of anticonvulsant, anxiolytic and anti-inflammatory properties. |
2021-06-08 |
2023-08-13 |
Not clear |
| Dvora Izgelov, Aviva Regev, Abraham J Domb, Amnon Hoffma. Using the Absorption Cocktail Approach to Assess Differential Absorption Kinetics of Cannabidiol Administered in Lipid-Based Vehicles in Rats. Molecular pharmaceutics. vol 17. issue 6. 2021-06-07. PMID:32352800. |
the work presented here compared the pharmacokinetic (pk) behavior of the non-intoxicating cannabinoid cannabidiol (cbd) in sesame oil |
2021-06-07 |
2023-08-13 |
rat |
| Staci A Gruber, Rosemary T Smith, M Kathryn Dahlgren, Ashley M Lambros, Kelly A Saga. No pain, all gain? Interim analyses from a longitudinal, observational study examining the impact of medical cannabis treatment on chronic pain and related symptoms. Experimental and clinical psychopharmacology. vol 29. issue 2. 2021-06-07. PMID:33764103. |
correlation analyses examined the relationship between changes in pain and other clinical measures, assessed the impact of cannabinoid exposure on pain and clinical ratings, and assessed whether baseline cannabis expectancies influenced outcome variables. |
2021-06-07 |
2023-08-13 |
Not clear |
| Ziva D Cooper, Suzette M Evans, Richard W Folti. Self-administration of inhaled delta-9-tetrahydrocannabinol and synthetic cannabinoids in non-human primates. Experimental and clinical psychopharmacology. vol 29. issue 2. 2021-06-07. PMID:34043398. |
cannabis and synthetic cannabinoids are abused in spite of possible adverse health consequences. |
2021-06-07 |
2023-08-13 |
monkey |
| Ziva D Cooper, Suzette M Evans, Richard W Folti. Self-administration of inhaled delta-9-tetrahydrocannabinol and synthetic cannabinoids in non-human primates. Experimental and clinical psychopharmacology. vol 29. issue 2. 2021-06-07. PMID:34043398. |
the current study investigated the reinforcing effects of an ecologically relevant mode of administration (inhalation) of delta-9-tetrahydrocannabinol (thc), the primary psychoactive component of cannabis, and three synthetic cannabinoids detected in synthetic cannabinoid products (jwh-018, jwh-073, and hu-210) in non-human primates (nhps). |
2021-06-07 |
2023-08-13 |
monkey |
| Kenneth Blum, Joseph Morgan, Jean Lud Cadet, David Baron, Paul R Carney, Jag Khalsa, Rajendra D Badgaiyan, Mark S Gol. Psychoactive Drugs Like Cannabis -Induce Hypodopaminergic Anhedonia and Neuropsychological Dysfunction in Humans: Putative Induction of Dopamine Homeostasis via Coupling of Genetic Addiction Risk Severity (GARS) testing and Precision Pro-dopamine Regulation (KB220). Neurology (E-Cronicon). vol 13. issue 4. 2021-06-06. PMID:34085060. |
changes in the laws have heightened interest and encouraged research into both cannabinoid products and the potential harms of cannabis use, addiction and intoxication. |
2021-06-06 |
2023-08-13 |
Not clear |